Penicillins and Cephalosporins to Penicillinase of Staphylococcus Aureus
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Susceptibility of Escherichia Coli to 3-Lactam Antibiotics
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 1994, p. 494-498 Vol. 38, No. 3 0066-4804/94/$04.00+0 Copyright © 1994, American Society for Microbiology Effect of Hyperproduction of TEM-1 1-Lactamase on In Vitro Susceptibility of Escherichia coli to 3-Lactam Antibiotics PEI-JUN WU,t KEVIN SHANNON,*t AND IAN PHILLIPS Department of Microbiology, United Medical and Dental Schools, St. Thomas' Hospital, London SE1 7EH, United Kingdom Received 21 July 1993/Returned for modification 4 November 1993/Accepted 4 January 1994 The susceptibility of 173 TEM-1-producing isolates of Escherichia coli was assessed by determination of MICs by the agar dilution method. MICs of amoxicillin, mezlocillin, cephaloridine, and, to a smaller extent, amoxicillin-clavulanic acid (but not cephalexin, cefuroxime, cefotaxime, ceftazidime, or imipenem) were higher for isolates that produced large amounts of f8-lactamase than for isolates that produced smaller amounts. The effect of fixed concentrations of clavulanic acid on resistance to amoxicillin was assessed for 34 selected TEM-1-producing isolates. Low concentrations of the inhibitor (0.5 to 1 ,ug/ml) reduced the amoxicillin MICs substantially for almost all the isolates, although the reductions were not sufficient to render any of the isolates amoxicillin susceptible. Higher concentrations of clavulanic acid had progressively greater effects on amoxicillin MICs, but even at 8 ,ug/ml some of the isolates with high P-lactamase activities remained resistant or only moderately susceptible to amoxicillin. All the isolates were inhibited by clavulanic acid (in the absence of amoxicillin) at concentrations of 16 to 32 ,ug/ml. TEM-1 ,-lactamase activity was inhibited in vitro by clavulanic acid, but not totally, with approximately 2% of the initial activity remaining at 2 ,ug/ml and 0.4% remaining at 8 ,guml. -
Dabigatran Amoxicillin Clavulanate IV Treatment in the Community
BEST PRACTICE 38 SEPTEMBER 2011 Dabigatran Amoxicillin clavulanate bpac nz IV treatment in the community better medicin e Editor-in-chief We would like to acknowledge the following people for Professor Murray Tilyard their guidance and expertise in developing this edition: Professor Carl Burgess, Wellington Editor Dr Gerry Devlin, Hamilton Rebecca Harris Dr John Fink, Christchurch Dr Lisa Houghton, Dunedin Programme Development Dr Rosemary Ikram, Christchurch Mark Caswell Dr Sisira Jayathissa, Wellington Rachael Clarke Kate Laidlow, Rotorua Peter Ellison Dr Hywel Lloyd, GP Reviewer, Dunedin Julie Knight Associate Professor Stewart Mann, Wellington Noni Richards Dr Richard Medlicott, Wellington Dr AnneMarie Tangney Dr Alan Panting, Nelson Dr Sharyn Willis Dr Helen Patterson, Dunedin Dave Woods David Rankin, Wellington Report Development Dr Ralph Stewart, Auckland Justine Broadley Dr Neil Whittaker, GP Reviewer, Nelson Tim Powell Dr Howard Wilson, Akaroa Design Michael Crawford Best Practice Journal (BPJ) ISSN 1177-5645 Web BPJ, Issue 38, September 2011 Gordon Smith BPJ is published and owned by bpacnz Ltd Management and Administration Level 8, 10 George Street, Dunedin, New Zealand. Jaala Baldwin Bpacnz Ltd is an independent organisation that promotes health Kaye Baldwin care interventions which meet patients’ needs and are evidence Tony Fraser based, cost effective and suitable for the New Zealand context. Kyla Letman We develop and distribute evidence based resources which describe, facilitate and help overcome the barriers to best Clinical Advisory Group practice. Clive Cannons nz Michele Cray Bpac Ltd is currently funded through contracts with PHARMAC and DHBNZ. Margaret Gibbs nz Dr Rosemary Ikram Bpac Ltd has five shareholders: Procare Health, South Link Health, General Practice NZ, the University of Otago and Pegasus Dr Cam Kyle Health. -
Charm II Antibiotic Analysis—Grain
Charm ii Antibiotic Analysis for Grain Products PROCeDURAL FLOWCHART + Binding Tracer Reagent Tablet Tablet Sample Charm ii 7600 analyzer Incubate START STOP Centrifuge Families DeteCteD = Aminoglycosides = Amphenicols/Chloramphenicol Resuspend = Beta-lactams = Macrolides = Sulfonamides C2Soft = Tetracyclines (optional) Count Results SAMPLE SIZe 50 to 100 g Computer Report SAMPLE PREPARATION Homogenize product in extraction solution for 60 seconds. Filter or centrifuge for 3 minutes. sample printout Test supernatant. Date = 08/23/10 preparation time Approximately 10-15 minutes, Time = 14:28:12 depending on the number of Operator = 1 samples. Time Counted = 60 Sample I.D. = 7764 ASSAY TIME Approximately 10 minutes, depending on drug family. Assay = Chloramphenicol CAPACITY 6 to 12 samples in assay, Lot# = ATBL 014 depending on drug family. Control Point = 2564 Sample (CPM) = 3676 Interpretation = Not Found Charm sciences, inc. 659 Andover Street, Lawrence, MA 01843, USA | Tel: +1.978.687.9200 | www.charm.com Charm ii Antibiotic Analysis for Grain Products Charm ii Kit Drug test sensitivity 1 (ppb) aminoglycosides (STIIHG) Streptomycin 2000 Dihydrostreptomycin 7500 Gentamicin 5000 aminoglycosides (GIIHG) Gentamicin 1000 Neomycin 500 Beta-lactams (PIIG) Penicillin-G 200 Amoxicillin 450 Ampicillin 400 Cephapirin 200 Ceftiofur 500 Cloxacillin 2500 Oxacillin 3750 Dicloxacillin 2500 Cefazolin 1500 Cefodroxil 1500 Cefotaxime 400 Cephalexin 1500 Cephradine 1500 Cefquinome 1000 Hetacillin 400 Nafcillin 3000 Penethamate 200 Piperacillin 1000 Ticarcillin 3500 Chloramphenicol Chloramphenicol 40 Florfenicol 160 & other amphenicols (CIIHG) Thiamphenicol 200 Chloramphenicol (AIIHG) Chloramphenicol 5 macrolides (EIIG) Erythromycin 1000 Tylosin 1000 Spiramycin 1000 Pirlimycin 2000 Tilmicosin 1000 Lincomycin 2500 sulfonamides (SMIIHG) Sulfamethazine 500 Sulfadimethoxine 200 Sulfathiazole 400 Sulfadiazine 200 tetracyclines (TIIHG) Tetracycline 100 Chlortetracycline 800 Oxytetracycline 800 1 Exceed 90% positive at a 95% confidence limit Charm sciences, inc. -
Flucloxacillin Capsules in This Leaflet: 1 What Flucloxacillin Capsules Are
Flucloxacillin capsules This information is a summary only. It does not contain all information about this medicine. If you would like more information about the medicine you are taking, check with your doctor or other health care provider. No rights can be derived from the information provided in this medicine leaflet. In this leaflet: If you take more than you should 1 What Flucloxacillin capsules are and what they are used for If you (or someone else) swallow a lot of capsules at the same time, or you think a 2 Before you take child may have swallowed any contact your nearest hospital casualty department 3 How to take or tell your doctor immediately. Symptoms of an overdose include feeling or 4 Possible side effects being sick and diarrhoea. 5 How to store If you forget to take the capsules 1 What Flucloxacillin capsules are and what they are used for Do not take a double dose to make up for a forgotten dose. If you forget to take a Flucloxacillin is an antibiotic used to treat infections by killing the bacteria that dose take it as soon as you remember it and carry on as before, try to wait about can cause them. It belongs to a group of antibiotics called “penicillins”. four hours before taking the next dose. Flucloxacillin capsules are used to treat: • chest infections If you stop taking the capsules • throat or nose infections Do not stop treatment early because some bacteria may survive and cause the • ear infections infection to come back. • skin and soft tissue infections • heart infections 4 Possible side effects • bones and joints infections Like all medicines, Flucloxacillin capsules can cause side effects, although not • meningitis everybody gets them. -
Clinical Management of Staphylococcus Aureus Bacteremia in Neonates, Children, and Adolescents
Clinical Management of Staphylococcus aureus Bacteremia in Neonates, Children, and Adolescents Brendan J. McMullan, BMed (Hons), FRACP, FRCPA,a,b,c,* Anita J. Campbell, MBBS, DCH, DipPID, FRACP,d,e,f,* Christopher C. Blyth, MBBS (Hons), PhD, DCH, FRACP, FRCPA,d,e,f,g J. Chase McNeil, BS, MD,h Christopher P. Montgomery, BA, MD,i,j Steven Y.C. Tong, MBBS (Hons), PhD, FRACP,k,l Asha C. Bowen, BA, MBBS, PhD, FRACPd,e,f,k,m Staphylococcus aureus is a common cause of community and health abstract – care associated bacteremia, with authors of recent studies estimating the aDepartment of Immunology and Infectious Diseases, incidence of S aureus bacteremia (SAB) in high-income countries between 8 Sydney Children’s Hospital, Randwick, New South Wales, , Australia; bSchool of Women’s and Children’s Health, and 26 per 100 000 children per year. Despite this, 300 children worldwide University of New South Wales, Sydney, New South Wales, have ever been randomly assigned into clinical trials to assess the efficacy Australia; cNational Centre for Infections in Cancer, of treatment of SAB. A panel of infectious diseases physicians with clinical University of Melbourne, Melbourne, Victoria, Australia; dDepartment of Infectious Diseases, Perth Children’s and research interests in pediatric SAB identified 7 key clinical questions. Hospital, Nedlands, Western Australia, Australia; The available literature is systematically appraised, summarizing SAB eWesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Nedlands, Western Australia, -
Summary of Product Characteristics
SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Augmentin 125 mg/31.25 mg/5 ml powder for oral suspension Augmentin 250 mg/62.5 mg/5 ml powder for oral suspension 2. QUALITATIVE AND QUANTITATIVE COMPOSITION When reconstituted, every ml of oral suspension contains amoxicillin trihydrate equivalent to 25 mg amoxicillin and potassium clavulanate equivalent to 6.25 mg of clavulanic acid. Excipients with known effect Every ml of oral suspension contains 2.5 mg aspartame (E951). The flavouring in Augmentin contains maltodextrin (glucose) (see section 4.4). This medicine contains less than 1 mmol sodium (23 mg) per ml, that is to say essentially ‘sodium- free’. When reconstituted, every ml of oral suspension contains amoxicillin trihydrate equivalent to 50 mg amoxicillin and potassium clavulanate equivalent to 12.5 mg of clavulanic acid. Excipients with known effect Every ml of oral suspension contains 2.5 mg aspartame (E951). The flavouring in Augmentin contains maltodextrin (glucose) (see section 4.4). This medicine contains less than 1 mmol sodium (23 mg) per ml, that is to say essentially ‘sodium- free’. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Powder for oral suspension. Off-white powder. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Augmentin is indicated for the treatment of the following infections in adults and children (see sections 4.2, 4.4 and 5.1): • Acute bacterial sinusitis (adequately diagnosed) • Acute otitis media • Acute exacerbations of chronic bronchitis (adequately diagnosed) • Community acquired pneumonia • Cystitis • Pyelonephritis 2 • Skin and soft tissue infections in particular cellulitis, animal bites, severe dental abscess with spreading cellulitis • Bone and joint infections, in particular osteomyelitis. -
Australian Public Assessment Refport for Ceftaroline Fosamil (Zinforo)
Australian Public Assessment Report for ceftaroline fosamil Proprietary Product Name: Zinforo Sponsor: AstraZeneca Pty Ltd May 2013 Therapeutic Goods Administration About the Therapeutic Goods Administration (TGA) • The Therapeutic Goods Administration (TGA) is part of the Australian Government Department of Health and Ageing, and is responsible for regulating medicines and medical devices. • The TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance), when necessary. • The work of the TGA is based on applying scientific and clinical expertise to decision- making, to ensure that the benefits to consumers outweigh any risks associated with the use of medicines and medical devices. • The TGA relies on the public, healthcare professionals and industry to report problems with medicines or medical devices. TGA investigates reports received by it to determine any necessary regulatory action. • To report a problem with a medicine or medical device, please see the information on the TGA website <http://www.tga.gov.au>. About AusPARs • An Australian Public Assessment Record (AusPAR) provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve a prescription medicine submission. • AusPARs are prepared and published by the TGA. • An AusPAR is prepared for submissions that relate to new chemical entities, generic medicines, major variations, and extensions of indications. • An AusPAR is a static document, in that it will provide information that relates to a submission at a particular point in time. • A new AusPAR will be developed to reflect changes to indications and/or major variations to a prescription medicine subject to evaluation by the TGA. -
Flucloxacillin 500Mg Capsules BP (Flucloxacillin Sodium)
PACKAGE LEAFLET: INFORMATION FOR THE USER Flucloxacillin 250mg Capsules BP Flucloxacillin 500mg Capsules BP (flucloxacillin sodium) Read all of this leaflet carefully before you start taking Warnings and precautions this medicine because it contains important information Talk to your doctor or pharmacist before taking this medicine if for you. you: - Keep this leaflet. You may need to read it again. • are 50 years of age or older - If you have any further questions, ask your doctor, • have other serious illness (apart from the infection this pharmacist or nurse. medicine is treating). - This medicine has been prescribed for you only. Do not • suffer from kidney problems, as you may require a lower pass it on to others. It may harm them, even if their signs dose than normal (convulsions may occur very rarely in of illness are the same as yours. patients with kidney problems who take high doses). - If you get any side effects, talk to your doctor or • suffer from liver problems, as this medicine could cause pharmacist. This includes any possible side effects not them to worsen. listed in this leaflet. See section 4. • are taking this medicine for a long time as regular tests of liver and kidney function are advised What is in this leaflet • are taking or will be taking paracetamol 1. What Flucloxacillin Capsules are and what they are used • are on a sodium-restricted diet. for • are giving this medicine to a newborn child 2. What you need to know before you take Flucolxacillin Capsules The use of flucloxacillin, especially in high doses, may reduce 3. -
WO 2010/025328 Al
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 4 March 2010 (04.03.2010) WO 2010/025328 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/00 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (21) International Application Number: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, PCT/US2009/055306 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 28 August 2009 (28.08.2009) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (25) Filing Language: English NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (26) Publication Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/092,497 28 August 2008 (28.08.2008) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): FOR¬ GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, EST LABORATORIES HOLDINGS LIMITED [IE/ ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, —]; 18 Parliament Street, Milner House, Hamilton, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, Bermuda HM12 (BM). -
Distinct Penicillin Binding Proteins Involved in the Division
Proc. Nat. Acad. Sci. USA Vol. 72, No. 8, pp. 2999- , August 1975 Biochemistry Distinct penicillin binding proteins involved in the division, elongation, and shape of Escherichia coli K12 (P-lactam antibiotics/slab gel electrophoresis/binding protein mutants) BRIAN G. SPRATT Department of Biochemical Sciences, Moffett Laboratories, Princeton University, Princeton, New Jersey 08540 Communicated by Arthur B. Pardee, May 20,1975 ABSTRACT The varied effects of #-lactam antibiotics on ied effects of f3-lactam antibiotics by their relative affinities cell division, cell elongation, and cell shape in E. coil are for three proteins involved in cell division, elongation, and shown to be due to the presence of three essential penicillin binding proteins with distinct roles in these three processes. the maintenance of cell shape. (A) Cell shape: ,-Lactams that specifically result in the pro- duction of ovoid cells bind to penicillin binding protein 2 METHODS (molecular weight 66,000). A mutant has been isolated that The organism used in these studies was E. coil K12 (strain fails to bind ft-lactams to protein 2, and that grows as round cells. (B) Cell division: f-Lactams that specifically inhibit cell KN126). It was grown in Difco Pennassay broth at 370 with division bind preferentially to penicillin binding protein 3 vigorous aeration and harvested at late logarithmic phase. (molecular weight 60,000). A temperature-sensitive cell divi- Mutants B6 and 6-30 were grown in the same medium at sion mutant has been shown to have a thermolabile protein 300. 3. (C) Cell elongation: One ft-lactam that preferentially inhib- Assay of Penicillin Binding Proteins. -
Staphylococcus Aureus Bloodstream Infection Treatment Guideline
Staphylococcus aureus Bloodstream Infection Treatment Guideline Purpose: To provide a framework for the evaluation and management patients with Methicillin- Susceptible (MSSA) and Methicillin-Resistant Staphylococcus aureus (MRSA) bloodstream infections (BSI). The recommendations below are guidelines for care and are not meant to replace clinical judgment. The initial page includes a brief version of the guidance followed by a more detailed discussion of the recommendations with supporting evidence. Also included is an algorithm describing management of patients with blood cultures positive for gram-positive cocci. Brief Key Points: 1. Don’t ignore it – Staphylococcus aureus isolated from a blood culture is never a contaminant. All patients with S. aureus in their blood should be treated with appropriate antibiotics and evaluated for a source of infection. 2. Control the source a. Removing infected catheters and prosthetic devices – Retention of infected central venous catheters and prosthetic devices in the setting of S. aureus bacteremia (SAB) has been associated with prolonged bacteremia, treatment failure and death. These should be removed if medically possible. i. Retention of prosthetic material is associated with an increased likelihood of SAB relapse and removal should be considered even if not clearly infected b. Evaluate for metastatic infections (endocarditis, osteomyelitis, abscesses, etc.) – Metastatic infections and endocarditis are quite common in SAB (11-31% patients with SAB have endocarditis). i. All patients should have a thorough history taken and exam performed with any new complaint evaluated for possible metastatic infection. ii. Echocardiograms should be strongly considered for all patients with SAB iii. All patients with a prosthetic valve, pacemaker/ICD present, or persistent bacteremia (follow up blood cultures positive) should undergo a transesophageal echocardiogram 3. -
Appraisal of Multifarious Brands of Cephradine for Their in Vitro Antibacterial Activity Against Varied Microorganisms
Appraisal of multifarious brands of Cephradine for their in vitro antibacterial activity against varied microorganisms Sajid Bashir1, Shamshad Akhtar1, Shahzad Hussain*2, Farnaz Malik2, Sidra Mahmood3, Alia Erum1 and Ume-Ruqiatulain1 1Department of Pharmacy, Sargodha University, Sargodha, Pakistan 2National Institute of Health, Islamabad, Pakistan 3Department of Bioinformatics and Biotechnology, International Islamic University, Islamabad, Pakistan Abstract: The astounding and exceptional growth of generic pharmaceutical Industry in Pakistan has raised certain questions for drug regulatory authorities contemplating their efficacy and quality. The current study focuses on assessing the in-vitro antimicrobial activity of 24 brands of Cephradine 500mg capsules against 4 different strains by employing standardized methods. Disk diffusion method was performed on all brands to look into the susceptibility and resistance patterns. Standard disk of 5µg Cephradine powder were used during evaluation. The zones of inhibitions were ranged from 24-40mm against S. aureus, 24-40mm against E. coli, 20-25mm against K. pneumonia and 19-23mm P. mirabilis. On the basis of mean value, the multinational brands were found to have better zone of inhibitions and were better than local Pharmaceutical companies but ANOVA cooperative study showed that all brands of Cephradine showed similar comparable results. Further investigations by employing MIC method, quality of raw material with special emphasis on the shelf-life, excepients and method of manufacturing will be needed to obtain more authenticated results. The price of National and Multinational brands ranges from Rs.156.00-212.00 for 10 capsules. It is concluded that Public health is at risk because of noticeable growing widespread curse of the manufacture and trade of sub-standard or below par pharmaceuticals.